Abstract

The analysis presented in the paper suggests an added value of radiomics features as prognostic and predictive biomarker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional information to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given the risk of overfitting.

View details

http://www.oraloncology.com/article/S1368-8375(17)30168-9/fulltext

Authors: Dan Ou, Pierre Blanchard, Silvia Rosellini, Antonin Levy, France Nguyen, Ralph T.H. Leijenaar, Ingrid Garberis, Philippe Gorphe, François Bidault, Charles Ferté, Charlotte Robert, Odile Casiraghi, Jean-Yves Scoazec, Philippe Lambin, Stephane Temam, Eric D
Publication Date: Tuesday, June 27, 2017